Navigation Links
China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates
Date:11/11/2009

ber 30, 2009 was $6.5 million, which is about 7% higher compared to the $6.1 million for the third quarter of 2008. Gross profit margin for the current quarter is 42%, compared to 49% in the third quarter of 2008. The lower gross profit margin in the third quarter of 2009 was due to faster revenue growth of lower margin products.

Selling and G&A expenses in the third quarter of 2009 rose to $1.3 million from $0.9 million as the company expanded its distribution network.

Given our good record on not losing any receivables, we now feel more comfortable in our ability to collect our account receivables. After analyzing our receivable collection history and also a number of other factors including macro economy and industry bad debt experience rates, management revised bad debt allowance estimates. The change in the estimate for bad debt reserve resulted in a benefit of $2.8 million for the third quarter of 2009.

Operating income for the third quarter of 2009, including the effect of the change in bad debt estimate, was $8.1 million, an increase of 72% from $4.7 million for the same period in 2008.

Net income for the third quarter of 2009 (which also includes the effect of the change in bad debt estimate) increased 69% to $7.2 million, up from $4.3 million reported in the same period of 2008. Diluted earnings per share was $0.17 in the third quarter of 2009, compared to $0.10 in the third quarter of 2008.

Balance Sheet

As of September 30, 2009, the Company had cash and cash equivalents of $3.8 million, which represented 4.0% of total assets, compared to $6.9 million, or 9.2% of total assets, as of December 31, 2008.

    Business Update
    -- On August 18, 2009, the Company announced that it has received official
       approval from China's State Food and Drug Administration ("SFDA") for
       the production of generic Omeprazole Sodium for Injection. Omepra
'/>"/>
SOURCE China Pharma Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2009 Results
2. China Medicine Announces Conference Call to Discuss Third Quarter 2009 Results
3. Monsanto Opens First Biotechnology Research Center in China
4. Chinas Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals
5. China-Biotics, Inc. Appoints New Vice President
6. Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process
7. China Biologic Named to Forbes Magazines Fifth Annual List of Asias 200 Best Under a Billion
8. China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China
9. China Medical Technologies Announces the SFDA Approval for its SPR System
10. China Integrated Energy, Inc. Announces Preliminary Third Quarter Financial Results and Increases Full Year Guidance
11. China Integrated Energy, Inc. Announces Eight Million Share Public Follow-On Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
(Date:12/24/2014)... The report provides basic information ... application and industry overview. This report also presents ... Production is separated by regions, technology and applications. ... downstream client survey, marketing channels, industry development trend ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... - Biomira Inc. (Nasdaq: BIOM ),(TSX: BRA) ... a randomized Phase II trial of the Stimuvax(R) ... results suggest that Stimuvax,combined with best supportive care ... stage IIIB NSCLC who had either responded or ...
... Calif., Sept. 5 Hyperion,Therapeutics, a biopharmaceutical company ... hepatology therapies for the,treatment of Urea Cycle Disorders ... million Series B financing. Leading the round was,Sofinnova ... and,NEA, all of Menlo Park, CA. WRF Capital ...
... 5 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced ... Bear Stearns 20th Annual Healthcare Conference on September,11, 2007 ... at the Grand,Hyatt Hotel in New York City. Jack ... provide a corporate overview of the,company and its clinical ...
Cached Biology Technology:Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 2Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 3Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 4Hyperion Therapeutics Secures $40 Million In Series B Round 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 3
(Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... starfish to carry out one of the most remarkable forms ... by first extending its stomach out of its mouth and ... and clams. The prey tissue is partially digested externally before ... digestive glands. , The researchers at Queen Mary, University of ...
... article published in this month,s issue of Pediatrics ... Medicine (BUSM) stress the importance of physicians recognizing that ... to make accurate health assessments for both mother and ... guidelines set a standardized risk assessment of herbal supplement ...
... will present the Society,s highest honor, the 2013 Wallace ... Professor Sir David Weatherall, MD, of the University of ... combining seminal discoveries, visionary translational research leadership, and a ... improve clinical care for thousands throughout the developing world. ...
Cached Biology News:Scientists uncover secrets of starfish's bizarre feeding mechanism 2Study finds physicians need to better recognize use of herbal supplements while breastfeeding 2Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 2Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 3Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 4
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Request Info...
Mouse Limitin MAb (Clone 183727)...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Biology Products: